New-wave insulin maker Thermalin Diabetes raises $5.9M

Thermalin Diabetes is picking up steam – and funding – as it develops a more concentrated and faster-acting version of insulin. The Boston and Cleveland-based company just raised $5.9 million from private investors in the first tranche of a Series B round. To date, it has raised about $15 million in equity and $8 million in NIH grants.